Re-treatment of Participants With Paget's Disease Using Zoledronic Acid

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The purpose of this study was to demonstrate that participants with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and later experienced a relapse can be successfully treated with a 5 milligram (mg) infusion of zoledronic acid.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00668200` - Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®	Phase 4

NCT number	NCT00740129
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 4
Start date	October 21, 2008
Completion date	March 14, 2011

Re-treatment of Participants With Paget's Disease Using Zoledronic Acid

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms